• DMXAA (Vadimezan): Advanced Insights into Tumor Vasculatu...

  2025-09-30

  Explore how DMXAA (Vadimezan, AS-1404) pioneers a dual paradigm as a vascular disrupting agent and immunomodulator for cancer research. Uncover advanced mechanisms, translational opportunities, and its unique value beyond current literature.

• Imatinib (STI571): Precision Targeting of Tumor–Stroma In...

  2025-09-29

  Explore how Imatinib (STI571), a selective protein-tyrosine kinase inhibitor, enables next-generation signal transduction and cancer biology research by dissecting tumor–stroma interactions in complex assembloid models. Discover unique insights into kinase specificity, tumor microenvironment modulation, and personalized drug response.

• DMXAA (Vadimezan): Next-Generation Tumor Vasculature Disr...

  2025-09-28

  Discover how DMXAA (Vadimezan, AS-1404) revolutionizes cancer biology research as a vascular disrupting agent and DT-diaphorase inhibitor. This article uniquely explores its integration with endothelial immune signaling and advanced anti-angiogenic strategies.

• DMXAA (Vadimezan, AS-1404): Next-Generation Vascular Disr...

  2025-09-27

  Explore the multifaceted role of DMXAA (Vadimezan, AS-1404) as a vascular disrupting agent for cancer research, highlighting its unique mechanisms in tumor vasculature disruption, apoptosis induction, and anti-angiogenic activity. This article provides new insights into DMXAA's integration with endothelial immune signaling and advanced applications in cancer biology.

• BGJ398 (NVP-BGJ398): Unveiling FGFR Inhibitor Precision i...

  2025-09-26

  Explore the advanced scientific applications of BGJ398 (NVP-BGJ398), a selective FGFR1/2/3 inhibitor, in both oncology research and developmental biology. This article uniquely bridges mechanistic cancer studies and emerging insights from comparative developmental models, offering a fresh perspective on FGFR-driven malignancies research.

• Torin2 and Apoptotic Signaling: Decoding mTOR Inhibition ...

  2025-09-25

  Explore how Torin2, a potent selective mTOR inhibitor, enables advanced cancer research by dissecting apoptosis beyond transcriptional loss. This article uniquely connects Torin2's molecular pharmacology to novel insights in regulated cell death, offering a deeper scientific perspective.

• BGJ398 (NVP-BGJ398): Unveiling FGFR2-Driven Cancer Biolog...

  2025-09-24

  Explore the advanced role of BGJ398, a potent FGFR inhibitor, in dissecting FGFR2-driven cancer mechanisms and developmental biology. This article uniquely bridges oncology research with emerging insights from comparative developmental models.

• BGJ398 (NVP-BGJ398): Dissecting FGFR Signaling and Cell F...

  2025-09-23

  Explore the mechanistic application of BGJ398 (NVP-BGJ398), a selective FGFR inhibitor, in elucidating FGFR-driven signaling pathways and apoptosis induction in cancer cells. This article highlights emerging research opportunities in developmental biology and oncology.

• L1023 Anti-Cancer Compound Library: Enabling Targeted Inh...

  2025-09-22

  The L1023 Anti-Cancer Compound Library provides a robust platform for high-throughput screening of cell-permeable anti-cancer compounds, accelerating the discovery of targeted inhibitors for oncogenic pathways. This article explores its application in the identification of molecular targets and the advancement of precision cancer therapeutics.

• L1023 Anti-Cancer Compound Library: Advancing High-Throug...

  2025-09-19

  Explore how the L1023 Anti-Cancer Compound Library empowers high-throughput screening of anti-cancer agents by offering a chemically diverse, cell-permeable collection targeting critical oncogenic pathways. This article discusses its unique value in uncovering molecular targets and accelerating translational cancer research.

• L1023 Anti-Cancer Compound Library: Accelerating Targeted...

  2025-09-18

  Explore how the L1023 Anti-Cancer Compound Library enables high-throughput screening of anti-cancer agents and advances targeted drug discovery. This article details its scientific utility for cancer research and highlights its unique value for identifying novel inhibitors.

• The hypothalamic pituitary adrenal HPA axis is a

  2025-03-03

  

  The hypothalamic-pituitary-adrenal (HPA) axis is a neuroendocrine system that is central to regulating responses to stress (Palazidou, 2012). In older persons, a high dysfunction of the HPA axis is observed (Otte et al., 2005) which may be enhanced by stimulatory effects of genes involved in the axi

• Composite soil samples were transported to

  2025-03-03

  

  Composite soil samples were transported to the laboratory and then dried, crushed and passed through a 2mm sieve was. Sample digestion and release of elements method Sposito was performed [15]. Accordingly, taking into account soil moisture to 2g soil samples 12.5ml of nitric acid was added 4M. Samp

• Our results showed suppressed autophagy in GECs under

  2025-03-03

  

  Our results showed suppressed autophagy in GECs under HAGG stimulation. Recently, people have paid more attentions on the roles of autophagy in lupus and tried to use autophagy regulators for therapy. Rapamycin could prevent the development of nephritis [49] and attenuate the established nephritis [

• The finding of the apelin APJ axis represents an

  2025-03-01

  

  The finding of the apelin/APJ axis represents an impressive event in cardiovascular studies. As a result of various experimental and clinical studies conducted in vivo and in vitro, it has been indicated that apelin/APJ is a crucial mediator of cardiovascular homeostasis, which takes part in the pat

14220 records 1/948 page Next 12345 下5页 Last page